GSK reiterated its full-year guidance after its new HIV and cancer treatments lifted profit ahead of analysts’ expectations ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Additionally, the company has developed next-generation drugs in respiratory and HIV areas that should help mitigate both branded and generic competition. We expect GSK to be a major competitor in ...

GSK’s majority-owned HIV unit ViiV has agreed licensing deals with a trio of generic manufacturers to make its recently-approved long-acting drug for pre-exposure prophylaxis (PrEP) available in ...

With Gilead Sciences sprinting to a likely approval next year for its long-acting pre-exposure prophylaxis (PrEP) drug for HIV, the California company has a chance to one-up GSK. While the British ...

GSK reported a mixed third-quarter performance on Wednesday, with a notable boost from specialty medicines helping to offset ...

GSK said that despite the fall in sales, Arexvy still had about a two-thirds share of the retail market, where most of the ...

GSK GSK-1.51%decrease; red down pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...